

September 27, 2012

OC Oerlikon Corporation AG – Ratio Change

DR CUSIP: 67084Q100

DR ISIN: US67084Q1004

DR Ticker Symbol: OERLY

Please be advised that The Bank of New York Mellon, as Depositary, will change the ratio of the OC Oerlikon Corporation AG, Depositary Receipt (“DR”) program from 20 DSs representing 1 Common share to 1 DS representing 2 Common shares, effective October 3, 2012.

Please note the following:

Old DR Ratio: 20 DSs : 1 Common share

New DR Ratio: 1 DS : 2 Common shares

Effective date for DR ratio change: October 3, 2012

Please note: A ratio change may impact the fees payable by ADR investors.

As there are no ADRs outstanding in the ADR facility, no distribution will be made. Our ADR inventory will automatically represent the new ratio. The CUSIP will remain the same.

Books will be closed from October 1, 2012 and will reopen on October 4, 2012 for Issuance and Cancellation transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis

Vice President

+1 212 815-4245

Ravi.davis@bnymellon.com

London

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold

Vice President

+852 2 840 9717

joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.